Lupin Pharmaceuticals to invest 250 million in new manufacturing plant in Coral Springs creating over 200 skilled jobs by 2030
Coral Springs, Florida – Lupin Pharmaceuticals, a global leader in drug manufacturing, has announced plans to construct a $250 million manufacturing plant in Coral Springs, a move expected to create over 200 skilled jobs by 2030. The announcement was made on Wednesday, signaling a major investment in both the local economy and the pharmaceutical industry.
The new 70,000-square-foot facility, located on five acres in the Coral Springs Park of Commerce, will focus on the production of more than 25 types of respiratory medicines. Among the products to be manufactured are albuterol inhalers, commonly used by children with asthma and military personnel, highlighting the plant’s significance in producing essential medications for vulnerable populations.
“This expansion of Lupin’s footprint in Coral Springs is a core part of our growth strategy,” said Christoph Funke, Lupin’s chief technical operations officer. Funke emphasized that the new facility represents both a commitment to advancing pharmaceutical manufacturing and an investment in the local workforce.
Lupin already maintains an existing operation in Coral Springs with its Advanced Inhalation Research Center located at 4006 NW 12th Ave. The new plant will complement this existing site, handling U.S. production of respiratory drugs, and further establishing Coral Springs as a hub for pharmaceutical innovation.
The company plans to invest heavily in research and development, infrastructure, and other capital expenditures over the next five years, signaling long-term growth and sustainability for the facility. This investment is expected to have a ripple effect throughout the local economy, creating additional opportunities in supporting industries such as logistics, maintenance, and administration.
To support the project, Lupin will receive tax credits and other state incentives designed to encourage business expansion and job creation in Florida. The company is collaborating with FloridaCommerce, the City of Coral Springs, Broward County, and the Greater Fort Lauderdale Alliance to ensure the project progresses smoothly and efficiently. These partnerships reflect a shared interest in boosting economic development while maintaining regulatory standards for high-tech manufacturing.
Local officials have expressed optimism about the plant’s impact on Coral Springs. Beyond job creation, the facility is expected to contribute to the city’s reputation as a center for advanced manufacturing and innovation, drawing talent and expertise from across the region. With a focus on respiratory medications, the plant will also play a critical role in public health initiatives, providing essential drugs to patients nationwide.
The project’s timeline indicates that the facility will be fully operational by 2030, offering ample opportunity for workforce training and recruitment in the coming years. For local residents, this represents a significant career opportunity in a variety of fields, from pharmaceutical production to engineering and quality assurance.
As Lupin moves forward with the Coral Springs project, the company emphasizes its commitment to innovation, quality, and community engagement. By combining advanced technology with a skilled workforce, the new plant is poised to become a cornerstone of Lupin’s U.S. operations and a major contributor to Coral Springs’ economic growth.
With the planned investment, the city can anticipate not only an influx of jobs but also a long-term boost in its profile as a hub for pharmaceutical excellence and research, positioning Coral Springs for a prominent role in the national healthcare manufacturing landscape.
This announcement marks a significant milestone for Lupin Pharmaceuticals and for Coral Springs, offering both economic opportunity and an enhanced focus on producing life-saving medications for communities across the country.
